PSNLHealthcare · Diagnostics & ResearchThe 5 Wall Street analysts covering Personalis, Inc. hold a median 12-month price target of $16 — +2.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 3 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Personalis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Volatility (16): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PSNL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Oct 2026 | BTIG | Downgrade | Neutral | — |
| 20 July 2026 | BTIG | Maintains | Buy | $11 → $16 |
| 20 July 2026 | BTIG | Maintains | Buy | — |
| 20 July 2026 | Lake Street | Downgrade | Hold | — |
| 20 July 2026 | Lake Street | Downgrade | Hold | $16 |
| 20 July 2026 | Needham | Downgrade | Hold | — |
| 20 July 2026 | Needham | Downgrade | Hold | — |
| 17 July 2026 | Needham | Maintains | Buy | $12 → $17 |
| 17 July 2026 | Needham | Maintains | Buy | — |
| 9 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 12 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 11 May 2026 | BTIG | Maintains | Buy | — |
| 5 Mar 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 27 Feb 2026 | Needham | Maintains | Buy | — |
| 11 Feb 2026 | BTIG | Maintains | Buy | — |
| 26 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 9 Jan 2026 | BTIG | Reiterates | Buy | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 11 Nov 2025 | BTIG | Maintains | Buy | — |
| 11 Nov 2025 | Guggenheim | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PSNL appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Personalis, Inc. returned +81.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 7% of US stocks
Cheaper than 12% of US stocks
Cheaper than 88% of US stocks
Higher than 78% of US stocks
Higher than 23% of US stocks
Higher than 12% of US stocks
Higher than 4% of US stocks
Higher than 21% of US stocks
Higher than 16% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Personalis, Inc. has a market value of $1.7B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $69.7M. The latest quarter grew 30.0% year on year.
Net income over the same four quarters: −$107.2M, a −153.8% net margin.
Diluted earnings per share, trailing twelve months: $−1.09.
Free cash flow in the twelve months to 30 June 2026: −$101.0M.
Trailing P/E: −17.3×; forward P/E: −16.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Personalis, Inc. employs 259 people — $269K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Personalis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Personalis reported financial and operational results for the third quarter ended September 30, 2026. It also announced the commercial launch of optional Real-Time Variant Tracker supplemental results in its NeXT Personal MRD test report.
Why it matters — PSNL watchers may note the new supplemental reporting feature as part of the company’s operational updates.
Business Wire published a legal notice urging Personalis shareholders to contact BFA Law about its ongoing investigation into the $16.25-per-share merger.
Why it matters — The notice concerns an investigation related to a merger involving Personalis and may be relevant to PSNL shareholders following the transaction.
Bleichmar Fonti & Auld LLP says it is investigating the going-private merger in which Tempus AI is taking Personalis private at $16.25 per share. The firm directed current Personalis stockholders to its website for more information.
Why it matters — The investigation concerns the terms of the transaction affecting Personalis shareholders.
Bleichmar Fonti & Auld LLP said it is investigating Personalis’s announced going-private merger with Tempus AI, in which Tempus is set to acquire all outstanding PSNL shares for $16.25 per share. The firm notified current stockholders to contact it.
Why it matters — The investigation concerns the terms of a proposed transaction that would take Personalis private.
Bleichmar Fonti & Auld LLP announced an investigation into the going-private merger under which Tempus AI is taking Personalis private at $16.25 per share. The firm invited current Personalis stockholders to seek additional information.
Why it matters — PSNL watchers may be interested in the investigation concerning the proposed merger and its terms.
The 5 Wall Street analysts covering Personalis, Inc. have a median 12-month price target of $16, with estimates ranging from $13 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Personalis, Inc., 1 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Personalis, Inc. 43 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Personalis, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +2.8% from the last close, and Ticker Nerd's factor model ranks Personalis, Inc. 43 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Personalis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PSNL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $16 over the next 12 months.
Personalis, Inc. returned +81.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Personalis, Inc. is a genomic diagnostics and data-analysis company focused on precision oncology and population genomics.
The most recent item we track (Business Wire, 4 Nov 2026): "Personalis Reports Third Quarter Results". Personalis reported financial and operational results for the third quarter ended September 30, 2026. It also announced the commercial launch of optional Real-Time Variant Tracker supplemental results in its NeXT Personal MRD test report.
Personalis, Inc. is a genomic diagnostics and data-analysis company focused on precision oncology and population genomics. Its current offerings include advanced sequencing tests that characterize tumors and immune-system interactions, supporting cancer diagnosis, treatment selection, disease monitoring, and pharmaceutical research. The company provides products such as ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which are designed to generate detailed genomic and immunologic insights from patient samples. Personalis, Inc. also delivers sequencing and analytical services for biopharmaceutical organizations developing cancer therapies, including personalized vaccines and immunotherapies, as well as for large-scale population sequencing initiatives. Its capabilities combine laboratory testing, bioinformatics, and data interpretation to help researchers and healthcare professionals understand disease biology and treatment response. Headquartered in Fremont, California, Personalis, Inc. serves the growing precision-medicine market by connecting high-resolution genomic information with clinical and drug-development applications.
CEO Mr. Christopher M. Hall · 259 employees · United States · https://www.personalis.com
